Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2024891 | 0.91 | CYP3A4 (0.60) | CYP3A4GPR119PIK3CDTGFBR1 | |
| SCHEMBL2020414 | 0.91 | CYP3A4 (0.56) | CYP3A4GPR119PIK3CDTGFBR1 | |
| SCHEMBL2017006 | 0.91 | CYP3A4 (0.59) | CYP3A4GPR119PIK3CD | |
| SCHEMBL2019907 | 0.89 | CYP3A4 (0.55) | CYP3A4GPR119PIK3CDTGFBR1 | |
| SCHEMBL2020920 | 0.88 | CYP3A4 (0.75) | CYP3A4GPR119 | |
| SCHEMBL2018346 | 0.87 | CYP3A4 (0.55) | CYP3A4GPR119PIK3CD | |
| SCHEMBL1128233 | 0.85 | CYP3A4 (0.78) | CYP3A4GPR119 | |
| SCHEMBL2016179 | 0.85 | CYP3A4 (0.53) | CYP3A4GPR119PIK3CD | |
| SCHEMBL2018302 | 0.84 | CYP3A4 (0.70) | CYP3A4GPR119 | |
| SCHEMBL2016794 | 0.82 | CYP3A4 (0.52) | CYP3A4GPR119PIK3CDTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | claimed |
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, GCKR, GID4 | CYP3A4 789/4885GPR119 1/4885PIK3CD 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.